

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington. DC 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
08/463,740	06/05/95	VON BORSTEL	R	1331-143

12M1/0121

NIXON AND VANDERHYE 1100 NORTH GLEBE ROAD 8TH FLOOR ARLINGTON VA 22201 EXAMINER KUNZ, G

ART UNIT PAPER NUMBER
1211 13

DATE MAILED:

01/21/98

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

	[Api	14			
	Application No.	Applicant(s)	Group Art Unit		
Office Action Summary	Examiner				
—The MAILING DATE of this communication app	ears on the cover she	et beneath the co	orrespondence address-		
Period for Response					
A SHORTENED STATUTORY PERIOD FOR RESPONSE IS MAILING DATE OF THIS COMMUNICATION.	S SET TO EXPIRE <i>T</i>	HREE MONTI	H(S) FROM THE		
 Extensions of time may be available under the provisions of 37 CF from the mailing date of this communication. If the period for response specified above is less than thirty (30) date of NO period for response is specified above, such period shall, by Failure to respond within the set or extended period for response to 	ays, a response within the s default, expire SIX (6) MOI	tatutory minimum of th	nirty (30) days will be considered timely.		
Status					
Responsive to communication(s) filed on	1-8-98		•		
This actions FINAL					
☐ Since this application is in condition for allowance exce accordance with the practice under Ex parte Quayle, 1			the merits is closed in		
Disposition of Claims					
Claim(s) 41 and 58-67 Of the above claim(s)	is/are p	is/are pending in the application.			
Of the above claim(s)	is/are v	is/are withdrawn from consideration.			
□ Claim(s)					
Claim(s) 41 and 58-67	is/are i	is/are rejected			
☐ Claim(s)		is/are	objected to		
☐ Claim(s)					
□ Claim(s)		require			
Application Papers					
☐ See the attached Notice of Draftsperson's Patent Drav	~				
☐ The proposed drawing correction, filed on is ☐ approved ☐ disapproved.					
☐ The drawing(s) filed on is/are ob	jected to by the Examir	er.			
☐ The specification is objected to by the Examiner.					
☐ The oath or declaration is objected to by the Examiner	•				
Priority under 35 U.S.C. § 119 (a)-(d)					
 □ Acknowledgment is made of a claim for foreign priority □ All □ Some* □ None of the CERTIFIED copies 	•				
received.	l\				
 received in Application No. (Series Code/Serial Nur received in this national stage application from the 					
*Certified copies not received:			···································		
Attachment(s)	M (3)		DTO 440		
			mary, PTO-413		
·			mal Patent Application, PTO-152		
 Notice of Draftsperson's Patent Drawing Review, PTO 	-948	⊔ Other			
88 463.74 0 Of	fice Action Summary				

U. S. Patent and Trademark Office PTO-326 (Rev. 3-97) Serial Number: 08/463,740 Page 2

Art Unit: 1211

Since this application is eligible for the transitional procedure of 37 CFR 1.129(a), and the fee set forth in 37 CFR 1.17(r) has been timely paid, the finality of the previous Office action is hereby withdrawn pursuant to 37 CFR 1.129(a). Applicant's first submission after final filed on has been entered.

Claims 41 and 58 - 67 are pending in the case.

All 35 USC statutes not cited in this Office action can be found cited in full in a previous Office action.

Claims 41 and 58 - 67 stand rejected under 35 USC 103 as being unpatentable over von Borstel et al. in view of Chu et al. for the reasons already of record on pages 2 - 3 of the Office action mailed 4-2-96.

The claims are directed to compositions comprising acylated uridine, cytidine, orotic acid and a uridine phosphorylase inhibitor. Von Borstel et al. discloses compositions comprising acylated uridine or cytidine but does not mention uridine phosphorylase inhibitors. Applicant argues that Chu et al. reference, which discloses compositions of uridine phosphorylase inhibitors, fails to cure this deficiency of von Borstel et al. because Chu et al. uses the phosphorylase inhibitors to potentiate the chemotherapeutic effect of pyrimidine nucleoside analogs, such as 5-fluorouridine, by preventing the degradation of said nucleoside analog. The applicant concludes that the person of ordinary skill in the art at the time of the invention would not have been motivated to combine the teaches of von Borstel et al. and Chu et al. Applicant's argument has been fully considered but is not deemed persuasive. The motivation for combining an acylated

Serial Number: 08/463,740 Page 3

Art Unit: 1211

uridine with a uridine phosphorylase inhibitor is either to inhibit the degradation of the nucleoside analog as taught by Chu et al. by elevating even further the blood and tissue levels of free uridine. Other motivation is also clear: to elevate the blood and tissue levels of free uridine by using two different compounds which act by different and distinct mechanisms. Von Borstel et al. cites numerous therapeutic advantages known in the prior art obtainable when blood and tissue uridine levels are elevated.

No claim is allowed.

All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.129(a) and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.129(a). Accordingly, THIS ACTION IS MADE FINAL even though it is a first action after the submission under 37 CFR 1.129(a). See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for response to this final action is set to expire THREE MONTHS from the date of this action. In the event a first response is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event will the statutory period for response expire later than SIX MONTHS from the date of this final action.

Serial Number: 08/463,740 Page 4

Art Unit: 1211

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Kunz, whose telephone number is (703) 308-4623. The examiner can normally be reached on Tuesday through Friday from 6:30 AM to 4:00 PM. The examiner can also be reached on alternate Mondays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John Kight, can be reached on (703) 308-0204. The fax phone number for this Group is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1235.

GARÝ L. KUNZ PRÍMARY FYAMINI

GROUP 1200

Gary L. Kunz, Ph.D. January 15, 1998